X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2035) 2035
Publication (265) 265
Book Review (39) 39
Book Chapter (23) 23
Conference Proceeding (8) 8
Book / eBook (5) 5
Data Set (1) 1
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1584) 1584
index medicus (1109) 1109
antifungal agents - therapeutic use (911) 911
male (759) 759
invasive aspergillosis (696) 696
female (673) 673
invasive pulmonary aspergillosis (585) 585
infectious diseases (565) 565
aspergillosis (564) 564
middle aged (535) 535
microbiology (519) 519
aspergillosis - drug therapy (473) 473
adult (468) 468
voriconazole (415) 415
pulmonary aspergillosis (409) 409
pharmacology & pharmacy (403) 403
fungal-infections (372) 372
diagnosis (359) 359
aged (353) 353
animals (343) 343
amphotericin-b (328) 328
treatment outcome (320) 320
risk factors (301) 301
antifungal agents - administration & dosage (298) 298
mycoses (298) 298
immunocompromised host (295) 295
invasive pulmonary aspergillosis - drug therapy (292) 292
aspergillus (267) 267
liposomal amphotericin-b (266) 266
antifungal agents (264) 264
antifungal agents - pharmacology (261) 261
health aspects (259) 259
immunology (256) 256
mycology (256) 256
invasive fungal-infections (249) 249
transplantation (248) 248
hematology (242) 242
therapy (236) 236
infections (231) 231
amphotericin b - therapeutic use (225) 225
mycoses - drug therapy (225) 225
adolescent (208) 208
aspergillosis - microbiology (207) 207
triazoles - therapeutic use (207) 207
epidemiology (204) 204
mortality (202) 202
care and treatment (198) 198
retrospective studies (196) 196
fungal infections (195) 195
aspergillosis - diagnosis (193) 193
itraconazole (192) 192
caspofungin (191) 191
research (190) 190
neutropenia (189) 189
child (187) 187
mice (179) 179
oncology (179) 179
invasive pulmonary aspergillosis - diagnosis (176) 176
amphotericin b (175) 175
neutropenic patients (175) 175
aspergillus fumigatus (173) 173
infection (160) 160
microbial sensitivity tests (160) 160
aspergillus fumigatus - drug effects (159) 159
cancer (158) 158
antifungal agents - adverse effects (157) 157
fungi (157) 157
fumigatus (155) 155
lung diseases, fungal - drug therapy (154) 154
antifungal therapy (149) 149
drug therapy, combination (146) 146
pharmacokinetics (145) 145
antifungal agents - pharmacokinetics (142) 142
invasive pulmonary aspergillosis - microbiology (142) 142
disease (140) 140
amphotericin b - administration & dosage (139) 139
lipopeptides (139) 139
stem-cell transplantation (138) 138
young adult (136) 136
efficacy (134) 134
respiratory system (134) 134
galactomannan (133) 133
risk-factors (132) 132
drug therapy (129) 129
veterinary sciences (128) 128
echinocandins - therapeutic use (127) 127
immunocompromised patients (127) 127
leukemia (127) 127
echinocandins (124) 124
prophylaxis (124) 124
patients (122) 122
aspergillus fumigatus - isolation & purification (120) 120
pyrimidines - therapeutic use (119) 119
cell transplant recipients (115) 115
disease models, animal (115) 115
medicine (115) 115
tomography, x-ray computed (115) 115
fluconazole (114) 114
neutropenia - complications (114) 114
aspergillus - isolation & purification (112) 112
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1972) 1972
French (28) 28
Spanish (27) 27
German (12) 12
Japanese (10) 10
Chinese (6) 6
Turkish (2) 2
Lithuanian (1) 1
Polish (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Infectious Diseases, ISSN 1058-4838, 5/2011, Volume 52, Issue 9, pp. 1123 - 1129
Background. Oral triazole therapy is well established for the treatment of invasive (IPA), allergic (ABPA), and chronic pulmonary (CPA) aspergillosis and is... 
Polymerase chain reaction | Antifungals | Aspergillus | Azoles | Triazoles | Aspergillosis | Sputum | ARTICLES AND COMMENTARIES | Allergic bronchopulmonary aspergillosis | Aspergillus fumigatus | Genetic mutation | DIAGNOSIS | INFECTIOUS DISEASES | SEVERE ASTHMA | METAANALYSIS | MICROBIOLOGY | ITRACONAZOLE | IMMUNOLOGY | INVASIVE ASPERGILLOSIS | PULMONARY ASPERGILLOSIS | SENSITIZATION | AZOLE RESISTANCE | ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS | PCR | Aspergillus fumigatus - drug effects | Sputum - microbiology | Lung - microbiology | Aspergillosis, Allergic Bronchopulmonary - microbiology | Humans | Aspergillosis, Allergic Bronchopulmonary - drug therapy | Antifungal Agents - therapeutic use | Bronchoalveolar Lavage Fluid - microbiology | Aspergillus fumigatus - isolation & purification | Culture Media | Polymerase Chain Reaction | Aspergillosis, Allergic Bronchopulmonary - epidemiology | Invasive Pulmonary Aspergillosis - epidemiology | Triazoles - therapeutic use | Antifungal Agents - pharmacology | Invasive Pulmonary Aspergillosis - drug therapy | Pulmonary Aspergillosis - drug therapy | DNA, Fungal - analysis | Drug Resistance, Fungal - genetics | Aspergillus fumigatus - genetics | Pulmonary Aspergillosis - microbiology | Triazoles - pharmacology | Pulmonary Aspergillosis - epidemiology | Invasive Pulmonary Aspergillosis - microbiology | Mutation | Chronic Disease | Drug resistance in microorganisms | Usage | Physiological aspects | Causes of | Lung diseases, Fungal | Research | Drug therapy | Health aspects | and Commentaries
Journal Article
Clinical Microbiology and Infection, ISSN 1198-743X, 12/2011, Volume 17, Issue 12, pp. 1882 - 1889
A prospective (2005–2007) hospital-based multicentre surveillance of EORTC/MSG-proven or probable invasive aspergillosis (IA) cases whatever the underlying... 
invasive aspergillosis | voriconazole | galactomannan | Epidemiology | outcome | Galactomannan | Invasive aspergillosis | Outcome | Voriconazole | INFECTIOUS DISEASES | MICROBIOLOGY | Aspergillus - classification | Prospective Studies | Humans | Middle Aged | Male | Antifungal Agents - therapeutic use | Incidence | Young Adult | Aged, 80 and over | Aspergillus - isolation & purification | Adult | Female | Seasons | Invasive Pulmonary Aspergillosis - epidemiology | Invasive Pulmonary Aspergillosis - drug therapy | France - epidemiology | Risk Factors | Invasive Pulmonary Aspergillosis - mortality | Drug Therapy, Combination - methods | Hospitals | Invasive Pulmonary Aspergillosis - microbiology | Mannans - blood | Adolescent | Aged | Immunocompromised Host | Analysis | Leukemia | Aspergillosis | Stem cells | Transplantation of organs, tissues, etc | Respiratory tract diseases | Transplantation | Risk factors | Trends | Transplants & implants | Mortality | Cell culture | Risk groups | Lung | stem cell transplantation | Central nervous system | Immunoproliferative diseases | Lipids | Regression analysis | Inflammatory diseases | Seasonal variations | Caspofungin | Geriatrics | Tumors | Life Sciences | Aspergillus | Microbiology and Parasitology | Invasive Pulmonary Aspergillosis | Mannans | Antifungal Agents | Drug Therapy, Combination | France
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 2017, Volume 216, Issue suppl_3, pp. S436 - s444
Journal Article
Respiratory Medicine, ISSN 0954-6111, 08/2018, Volume 141, pp. 121 - 131
Notable progress has been made in the past years in the classification, diagnosis and treatment of pulmonary aspergillosis. New criteria were proposed by the... 
Aspergillus | Chronic pulmonary aspergillosis | Invasive aspergillosis | Pulmonary aspergillosis | Allergic bronchopulmonary aspergillosis | BRONCHOALVEOLAR LAVAGE FLUID | SEVERE ASTHMA | CARDIAC & CARDIOVASCULAR SYSTEMS | COLONY-STIMULATING FACTOR | CHRONIC GRANULOMATOUS-DISEASE | RANDOMIZED-TRIAL | CLINICAL CHARACTERISTICS | INVASIVE FUNGAL-INFECTIONS | RESPIRATORY SYSTEM | GALACTOMANNAN ANTIGEN | CYSTIC-FIBROSIS | Invasive Pulmonary Aspergillosis - drug therapy | Recurrence | Triazoles - administration & dosage | Pulmonary Aspergillosis - drug therapy | Prognosis | Pyridines - administration & dosage | Humans | Environmental Exposure - prevention & control | Pulmonary Aspergillosis - diagnosis | Aspergillosis, Allergic Bronchopulmonary - drug therapy | Pulmonary Aspergillosis - microbiology | Invasive Pulmonary Aspergillosis - diagnosis | Antifungal Agents - therapeutic use | Environmental Exposure - adverse effects | Fungi | Nitriles - administration & dosage | Pulmonary Aspergillosis - epidemiology | Aspergillus - isolation & purification | Aspergillosis, Allergic Bronchopulmonary - diagnosis | Nitriles - therapeutic use | Pyridines - therapeutic use | Triazoles - therapeutic use | Sleep disorders | Medical colleges | Triazoles | Communicable diseases | Cystic fibrosis | Respiratory agents | Drug approval | Risk factors | Therapy | Regulatory agencies | Medical imaging | Microbiology | Mycology | Medical treatment | Medical services | Molds | Infections | Medical diagnosis | Patients | Asthma | Infectious diseases | Classification | Aspergillosis | Chronic obstructive pulmonary disease | Diagnosis | Clinical microbiology | Immune system
Journal Article
Drug Resistance Updates, ISSN 1368-7646, 2015, Volume 21-22, pp. 30 - 40
Journal Article